1. Home
  2. RCUS vs XHR Comparison

RCUS vs XHR Comparison

Compare RCUS & XHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • XHR
  • Stock Information
  • Founded
  • RCUS 2015
  • XHR 2007
  • Country
  • RCUS United States
  • XHR United States
  • Employees
  • RCUS N/A
  • XHR N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • XHR Real Estate Investment Trusts
  • Sector
  • RCUS Health Care
  • XHR Real Estate
  • Exchange
  • RCUS Nasdaq
  • XHR Nasdaq
  • Market Cap
  • RCUS 1.2B
  • XHR 1.3B
  • IPO Year
  • RCUS 2018
  • XHR N/A
  • Fundamental
  • Price
  • RCUS $17.35
  • XHR $13.06
  • Analyst Decision
  • RCUS Buy
  • XHR Buy
  • Analyst Count
  • RCUS 8
  • XHR 6
  • Target Price
  • RCUS $26.50
  • XHR $13.83
  • AVG Volume (30 Days)
  • RCUS 1.2M
  • XHR 617.4K
  • Earning Date
  • RCUS 11-05-2025
  • XHR 10-31-2025
  • Dividend Yield
  • RCUS N/A
  • XHR 4.25%
  • EPS Growth
  • RCUS N/A
  • XHR 193.03
  • EPS
  • RCUS N/A
  • XHR 0.62
  • Revenue
  • RCUS $262,000,000.00
  • XHR $1,075,161,000.00
  • Revenue This Year
  • RCUS N/A
  • XHR $4.71
  • Revenue Next Year
  • RCUS N/A
  • XHR $2.85
  • P/E Ratio
  • RCUS N/A
  • XHR $21.27
  • Revenue Growth
  • RCUS 6.07
  • XHR 4.81
  • 52 Week Low
  • RCUS $6.50
  • XHR $8.55
  • 52 Week High
  • RCUS $18.98
  • XHR $16.50
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 64.78
  • XHR 43.90
  • Support Level
  • RCUS $16.41
  • XHR $12.75
  • Resistance Level
  • RCUS $18.42
  • XHR $13.66
  • Average True Range (ATR)
  • RCUS 1.17
  • XHR 0.32
  • MACD
  • RCUS 0.04
  • XHR 0.04
  • Stochastic Oscillator
  • RCUS 75.30
  • XHR 52.02

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About XHR Xenia Hotels & Resorts Inc.

Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other. Xenia's revenue is divided between room, food and beverage, and other. The firm's customer groups include transient business, group business, and contract business.

Share on Social Networks: